Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2016-08-03 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 1047G' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES' concerning an acquisition/disposal of voting rights, specifically noting a change in holding from 6.5% to 9.84% by Vivo Ventures VII, LLC and related entities. This type of mandatory disclosure regarding significant changes in share ownership thresholds falls directly under the definition of Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is the more specific category for this content type.
2016-08-03 English
Holding(s) in Company - Replacement
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the header 'RNS Number' and contains a standardized notification format titled 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This form details changes in significant share ownership thresholds (crossing from 0% to 4.3%) by a specific entity (BioDiscovery 4 FPCI). This type of filing, which reports changes in major shareholdings, directly corresponds to the Major Shareholding Notification category.
2016-08-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with "RNS Number : 9994F" and contains the header "TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES". This format is characteristic of regulatory notifications concerning changes in significant shareholdings, which aligns directly with the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2016-08-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 8834F' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES', specifically reporting an acquisition/disposal of voting rights by 'Growth Equity Opportunities IV, LLC' and crossing the 8% threshold. This type of filing, which reports changes in significant share ownership, corresponds directly to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific nature of the content (major shareholder change) makes MRQ a more precise classification than the general RNS fallback.
2016-08-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with an 'RNS Number' and contains the header 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This format is characteristic of regulatory notifications filed with a stock exchange (in this case, implied to be the London Stock Exchange via RNS). Specifically, it details an acquisition or disposal of voting rights by a major shareholder (OrbiMed Private Investments VI, LP), crossing the 5% threshold. This falls under the category of Major Shareholding Notification (MRQ) or, more broadly, a Regulatory Filing (RNS). Since MRQ is a specific category for changes in significant share ownership, it is the most precise fit. The document is a direct notification, not an announcement of a report.
2016-08-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 8336F' and contains the header 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This format is characteristic of regulatory notifications filed with a stock exchange, specifically referencing the RNS (Regulatory News Service) system used by the London Stock Exchange. The content details changes in major shareholdings (crossing thresholds of 3%, 4%, 5%, 6%) by specific entities (Abingworth LLP, Abingworth Bioventures VI LP). This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is a more specific and accurate classification than the general 'RNS' fallback.
2016-08-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.